2024 ICD-10-CM Diagnosis Code C48.0

Malignant neoplasm of retroperitoneum

C48.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
The 2024 edition of ICD-10-CM C48.0 became effective on October 1, 2023.
This is the American ICD-10-CM version of C48.0 – other international versions of ICD-10 C48.0 may differ.

The following code(s) above C48.0 contain annotation back-references

that may be applicable to C48.0:

Approximate Synonyms

Clinical Information

A primary or metastatic malignant neoplasm involving the retroperitoneum. The vast majority of cases are carcinomas, lymphomas, or sarcomas.

ICD-10-CM C48.0 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
843 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with mcc
844 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with cc
845 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without cc/mcc

Convert C48.0 to ICD-9-CMCode History

2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
2017 (effective 10/1/2016): No change
2018 (effective 10/1/2017): No change
2019 (effective 10/1/2018): No change
2020 (effective 10/1/2019): No change
2021 (effective 10/1/2020): No change
2022 (effective 10/1/2021): No change
2023 (effective 10/1/2022): No change
2024 (effective 10/1/2023): No change

Code annotations containing back-references to C48.0: